Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 15/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.51 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | PLAT | P00750 | 1/20 | 0.49 |
| ▸ | HPN | P05981 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8613521 | 0.87 | CHEK2 (0.79) | CHEK2PKN1PKN2PLAUPRSS1 | |
| SCHEMBL1251120 | 0.86 | HDAC6 (0.52) | CHEK2CHEK1HDAC3HDAC1HDAC2 | |
| SCHEMBL3916628 | 0.84 | CHEK2 (0.80) | CHEK2PKN1PKN2 | |
| SCHEMBL3926645 | 0.83 | CHEK2 (0.83) | CHEK2 | |
| SCHEMBL13078192 | 0.82 | CHEK2 (0.51) | CHEK2CHEK1PKN1PKN2 | |
| SCHEMBL29517866 | 0.82 | CHEK2 (0.67) | CHEK2F2F10 | |
| SCHEMBL179156 | 0.82 | CHEK2 (0.67) | CHEK2F2F10 | |
| SCHEMBL1380709 | 0.82 | CHEK2 (0.81) | CHEK2 | |
| SCHEMBL1378039 | 0.81 | CHEK2 (0.58) | CHEK2CHEK1 | |
| SCHEMBL29002011 | 0.80 | F2 (0.76) | CHEK2PKN1PKN2F2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482373-B2 | Bis-benzimidazoles and related compounds as potassium channel modulators | ICAGEN, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070027200-A1 | Bis-benzimidazoles and related compounds as potassium channel modulators | ICAGEN, INC. (US) | 2007-02-01 | — | — | US | disclosed |
| US-7132439-B2 | Bis-benzimidazoles and related compounds as potassium channel modulators | ICAGEN, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20040029925-A1 | Bis-benzimidazoles and related compounds as potassium channel modulators | ICAGEN, INC. (US) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027200-A1 | Bis-benzimidazoles and related compounds as potassium channel modulators | KCNJ2, KCNA3, KCNB2 | CHEK2 2776/4885CHEK1 3067/4885PKN1 448/4885 |
| US-20040029925-A1 | Bis-benzimidazoles and related compounds as potassium channel modulators | KCNJ2, KCNA3, KCNB2 | CHEK2 2776/4885CHEK1 3067/4885PKN1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.